Drug Profile
Mavodelpar - Reneo Pharmaceuticals
Alternative Names: HPP 593; REN-001 - Reneo PharmaceuticalsLatest Information Update: 23 Feb 2024
Price :
$50
*
At a glance
- Originator Novo Nordisk
- Developer High Point Pharmaceuticals; Reneo Pharmaceuticals; vTv Therapeutics LLC
- Class Acetic acids; Alkenes; Alkynes; Antihyperglycaemics; Antihyperlipidaemics; Fluorobenzenes; Morpholines; Phenyl ethers; Small molecules
- Mechanism of Action Peroxisome proliferator-activated receptor delta agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Inborn error metabolic disorders; Mitochondrial myopathies
- Discontinued Diabetes mellitus; Dyslipidaemias; Glycogen storage disease type V; Muscle fatigue
Most Recent Events
- 09 Feb 2024 Reneo Pharmaceuticals terminates the phase II/III STRIDE AHEAD trial for Mitochondrial myopathies in Australia, Germany, Denmark, Hungary, Belgium, Netherlands, Spain, Canada, France, Italy, New Zealand and United Kingdom (PO), because the parent study failed to show therapeutic effect (NCT05267574) (EudraCT2021-003471-34)
- 14 Dec 2023 Suspended - Phase-I for Inborn error metabolic disorders in France (PO)
- 14 Dec 2023 Suspended - Phase-I for Inborn error metabolic disorders in Spain (PO)